The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IV.a

Bronchospasm - Wheezing - Asthma

Publications

Ehrmann S, Barbier F, Demiselle J, Quenot JP, Herbrecht JE, Roux D, Lacherade JC, Landais M, Seguin P, Schnell D, Veinstein A, Gouin P, Lasocki S, Lu Q, Beduneau G, Ferrandiere M, Plantefève G, Dahyot-Fizelier C, Chebib N, Mercier E, Heuzé-Vourc'h N, Resp

Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.

The New England journal of medicine. 2023;389(22):2052-2062

Golia A, Mahmood BR, Fundora Y, Thornby KA, Chahine EB

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease.

The Senior care pharmacist. 2020;35(4):162-170

Brodt AM, Stovold E, Zhang L

Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review.

The European respiratory journal. 2014;44(2):382-93

Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J

Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.

Journal of aerosol medicine and pulmonary drug delivery. 2011;24(4):183-90